Technology evaluation: Colostrinin (ReGen)Rattray, M. (2005) Technology evaluation: Colostrinin (ReGen). Current Opinion in Molecular Therapeutics, 7 (1). pp. 78-84. ISSN 1464-8431 Full text not archived in this repository. It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing. Official URL: http://www.ncbi.nlm.nih.gov/pubmed/15732533 Abstract/SummaryReGen Therapeutics is developing Colostrinin, a polypeptide complex derived from ovine colostrums, for the potential treatment of Alzheimer's disease. The compound is currently undergoing phase II clinical trials.
Deposit Details University Staff: Request a correction | Centaur Editors: Update this record |